Please login to the form below

Not currently logged in
Email:
Password:

New use cleared for Shire ADHD drug

The FDA has approved Shire's ADHD drug Intuniv for the new indication of adjunctive therapy to stimulants in children and adolescents aged six to 17

The US Food and Drug Administration has approved Shire's marketed attention deficit hyperactivity disorder drug Intuniv (guanfacine) for the new indication of adjunctive therapy to stimulants in children and adolescents aged six to 17. 

The approval makes the drug the only once-daily ADHD medication approved for administration as adjunctive therapy to stimulants. It is intended to offer a new option for patients who are having a suboptimal response to their existing stimulant therapy.

"This approval marks a significant development in our ADHD portfolio – one that may help to address symptoms that many children with ADHD may experience while on stimulant treatment," said Michael Yasick, senior vice president of Shire's ADHD business unit.

The new approval is based on results from a nine-week placebo-controlled study of Intuniv in combination with each subject's current stimulant medication. Shire noted that the effectiveness of Intuniv for more than nine weeks has not been systematically evaluated. 

Intuniv, a nonstimulant selective alpha-2A agonist, is a long-acting version of the blood-pressure drug guanfacine, which is sold for the cardiovascular use by Promius Pharmaceuticals under the brandname Tenex as well as by generic drugmakers. 

Shire's original approval of the drug as a treatment for ADHD was issued by the FDA in 2009 and, like the new approval, covers patients aged six to 17. Intuniv brought in $166m in sales in its first full year on the market. 

The company's ADHD portfolio also includes the extended-release drug VyVanse (lisdexamfetamine dimesylate), which was approved in the US in 2007, and Adderall XR (dextroamphetamine and amphetamine), which was approved in 2001 and has patent protection until 2019 but will face generic competition sooner under the terms of settlements Shire made in response to patent challenges. 

1st March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics